Home
Resource
Tyrosine-derived nanoparticles for the topical treatment of psoriasis
PDF
PDF format is widely accepted and good for printing.
Plug-in required
PDF-1(5.26 MB)
Citation & Export
View Usage Statistics
Staff View

Citation & Export
Hide

Simple citation

Kilfoyle, Brian E.. Tyrosine-derived nanoparticles for the topical treatment of psoriasis. Retrieved from https://doi.org/doi:10.7282/T3513X9B

Export

Click here for information about Citation Management Tools at Rutgers.

Statistics
Hide

Description

TitleTyrosine-derived nanoparticles for the topical treatment of psoriasis
NameKilfoyle, Brian E. (author); Michniak-Kohn, Bozena (chair); Minko, Tamara (internal member); You, Guofeng (internal member); Gumaste, Anand (outside member); Rutgers University; Graduate School - New Brunswick
Date Created2011
Other Date2011-10 (degree)
SubjectPharmaceutical Science, Psoriasis--Treatment, Nanoparticles, Tyrosine
Extentxxxi, 186 p. : ill.
DescriptionAt the New Jersey Center for Biomaterials, a potential topical psoriasis therapy consisting of tyrosine-derived polymeric micelles (TyroSpheres™) with encapsulated drug has been developed. These TyroSpheres™ are composed of copolymers with hydrophobic blocks of oligomers of desaminotyrosyl tyrosine esters and diacids and hydrophilic blocks of poly(ethylene glycol). Encapsulated drugs include a vitamin D3 analogue, betamethasone dipropionate, and paclitaxel. Drug-loaded TyroSpheres™ offer: 1) reproducible particle sizes, 2) control of drug release rates, 3) enhancement of drug stability, 4) increased solubility by high encapsulation capacity, 5) lack of short-term cytotoxicity, and 6) the ability to improve drug delivery into the skin. Additionally, TyroSpheres™ can be incorporated into an elegant viscous formulation for skin application with no impact on homogeneity, release, or skin distribution. Analysis has revealed that TyroSpheres™ are stable for up to 4 months, significantly limiting their shelf-life potential. By implementing a rational design, research on the preparation of a dry formulation of TyroSpheresTM has been undertaken, resulting in a fully re-constitutable formulation that has demonstrated complete stability to date (6 months). A two year-long stability study has been initiated to track the properties of this formulation over time. TyroSpheres™ address the requirements of a pharmaceutically acceptable skin drug delivery carrier and offer potential in the treatment of psoriasis since they allow delivery of difficult to uptake drugs to skin strata where the disease originates.
NotePh.D.
NoteIncludes bibliographical references
Noteby Brian E. Kilfoyle
Genretheses, ETD doctoral
Persistent URLhttps://doi.org/doi:10.7282/T3513X9B
Languageeng
CollectionGraduate School - New Brunswick Electronic Theses and Dissertations
Organization NameRutgers, The State University of New Jersey
RightsThe author owns the copyright to this work.
Version 8.5.5
Rutgers University Libraries - Copyright ©2024